Theralase Technologies Inc. V.TLT

Why was TLD1433 preferred over TLD1633?

[Eoganacht]

The answer is in Dr. McFarland's (and Dr. Lilge's) paper describing the development of TLD1433. The entire text is available online at:

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433

"...Our current hypothesis is that TLD1433 and TLD1633 act as supercatalysts, producing more than one ROS or other reactive species per photon absorbed per molecule when electron-transfer reactions are involved ...

 

Considering the potency of TLD1633, it may seem odd that TLD1433 was selected instead. TLD1433 was prioritized over the other compound for a number of reasons, including:

(1) there were more synthetic steps required for producing TLD1633, and those steps were low yielding (unoptimized at that time) and required expensive catalysts,

(2) there was more batch-to-batch variability with TLD1633,

(3) the theranostic capacity of TLD1433 was greater (i.e., its luminescence quantum yield was higher), and

(4) we were relatively far along in our pre-clinical studies with TLD1433 by the time the synthesis of TLD1633 was optimized to produce the larger batches required for in vivo studies...."

[Oilminerdeluxe]

I suspect a few of us will check the mailbox an extra time or two in the coming days just in case something drops. Hopefully the action will pick up after that and make things more interesting. At least easier to endure. 

[jicoop]

Thanks Eoga for the further info on TLD1633 . Maybe 1633 will be used for brain or other cancers down the road. Going to try and find the news release soon that I'm sure said they had something that killed at a billion times more efficiently , gotta be somewhere, gonna take some time but markets closed today and I just have to get at it. Oh, and I'll take the Porsche Taycan Turbo S Cross

[jicoop]

Well, found this for starters, not quite what I remember, but then again forgetting things seems to be getting easier and easier the older I get.  This is excerpt from August 22, 2017 news release from TLT .  I will keep looking, but I think the highlighted part should be known by every oncologist in the world. The most advanced PDC, TLD-1433, developed by McFarland and Theralase, has